Sera Prognostics Shines at H.C. Wainwright Investment Conference
Sera Prognostics Inc., also known as The Pregnancy Company (NASDAQ: SERA), is dedicated to improving maternal and neonatal health through innovative diagnostic solutions. The company is excited to announce its upcoming presentation at the H.C. Wainwright 26th Annual Global Investment Conference, where it will showcase its latest advancements and insights into its transformative technologies.
Presentation Details
At the event, Zhenya Lindgardt, the President and CEO of Sera Prognostics, will present the groundbreaking work the company has been doing in pregnancy health. This presentation is set for Wednesday, September 11, 2024, at 10:00 a.m. ET, and will offer an update on the company’s accomplishments and future strategic direction.
Access the Presentation
For those interested in Sera's developments, the presentation will be streamed live via a webcast, with a replay available shortly after. You can find these resources on the Investors page of Sera's official website.
About Sera Prognostics
Sera Prognostics is committed to transforming health diagnostics by prioritizing precision in pregnancy care. The company strives to provide essential pregnancy information early on, enabling healthcare providers to make timely decisions that enhance health outcomes for both mothers and their newborns. This proactive approach not only improves patient care but also aims to lower healthcare costs associated with pregnancy complications.
Innovative Solutions for Preterm Birth
Among Sera Prognostics' key offerings is the PreTRM® Test, a groundbreaking diagnostic tool that evaluates the risk of premature delivery by analyzing blood biomarkers during the critical early stages of pregnancy. This test empowers healthcare professionals with personalized risk assessments, allowing for proactive interventions in pregnancies deemed at risk.
Understanding Preterm Birth
Preterm birth, which occurs before 37 weeks of gestation, poses a significant challenge in maternal health, leading to heightened risks of complications for newborns. The consequences of preterm birth can be severe, often resulting in long-term health issues such as developmental delays and chronic conditions.
The Importance of the PreTRM® Test
The PreTRM® Test is recognized as the only widely validated blood-based biomarker test for predicting spontaneous preterm birth in asymptomatic pregnancies, making it a crucial tool. It allows healthcare providers to identify women who may require additional support and resources, enabling the creation of personalized care plans early in their pregnancy journey.
Support for Mothers and Babies
The insights obtained from the PreTRM Test not only assist healthcare professionals in managing pregnancy risks but also empower mothers with valuable knowledge about their health, enhancing their overall pregnancy experience.
Company Values and Future Outlook
Sera Prognostics is dedicated to innovation, safety, and patient-centered care in all its initiatives, ensuring that women receive the highest level of support throughout their pregnancies. As the company continues to grow and adapt, it remains steadfast in its commitment to advancing maternal diagnostics and improving health outcomes for all.
Frequently Asked Questions
What is the focus of Sera Prognostics?
Sera Prognostics is focused on improving maternal and neonatal health through innovative diagnostic solutions.
What is the PreTRM® Test?
The PreTRM® Test is a blood-based biomarker test that assesses the risk of spontaneous preterm birth in asymptomatic pregnancies.
When will Sera present at H.C. Wainwright?
Sera Prognostics will present on September 11, 2024, at 10:00 a.m. ET.
How can I view the presentation?
The presentation will be available via a live webcast on the Investors page of Sera's website, with a replay accessible shortly after.
What are the implications of preterm birth?
Preterm birth can lead to significant short- and long-term health complications for newborns, resulting in increased healthcare costs and resource demands.
